1561 Buckeye Drive
About Bigfoot BiomedicalBigfoot Biomedical was founded by people affected by and living with Type 1 Diabetes (T1D) and is committed to leveraging data, people, and smart technology to create a connected ecosystem of solutions that will deliver improved outcomes valued by patients, providers, and payers.
Bigfoot's investigational automated insulin delivery system, otherwise known as an "artificial pancreas," was inspired by a proof-of-concept system that's been used for over 50,000 hours.
CEO: Jeffrey Brewer
Chief Technology Officer: Bryan Mazlish
Chief Engineer: Lane Desborough
CFO: Jon Brilliant
18 articles about Bigfoot Biomedical
Bigfoot Unity® Demonstrates Strong Glycemic Control Among People with Type 2 Diabetes in Real-World Retrospective Analysis
Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, presented real-world data from its late-breaking abstract presented at the American Diabetes Association 82nd Annual Scientific Sessions.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Bigfoot Clinic Hub™ Puts Critical Data at Fingertips of Health Care Professionals to Enable Proactive Care of their Patient Populations with Type 1 and Type 2 Diabetes
Since launching in late summer 2021, the innovative Bigfoot Unity™ Diabetes Management Program and its Bigfoot Clinic Hub™ are demonstrating that technology can help transform how health care professionals manage their patient populations on multiple daily injections of insulin.
Bigfoot Biomedical® Receives FDA Clearance for Bigfoot Unity™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes
Bigfoot Biomedical ® Receives FDA Clearance for Bigfoot Unity ™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes Integrated with Abbott’s FreeStyle ® Libre 2 system, the Bigfoot Unity System is the first and only to translate continuously monitored glucose data into on-demand insulin dose recommendations displayed right on the pen-cap screen for ease of use 1
Bigfoot Biomedical® Builds Out Experienced Commercial Team, Announces New Hires
Company focused on broadening access to innovative solutions for people with type 1 and type 2 diabetes and designing high-touch customer care experiences
Bigfoot Biomedical® Appoints Jim Malone MD Chief Medical Officer
Bigfoot Biomedical, Inc. announced today the appointment of Dr. Jim Malone as Chief Medical Officer. Dr. Malone, an endocrinologist specializing in diabetes, spent 12 years in clinical practice and 21 years in clinical research, where he developed diabetes pr
Bigfoot Biomedical® Closes Series C Financing with $55 Million as Company Readies for FDA Submission of Bigfoot Unity
Bigfoot Biomedical, Inc. announced today that the company has raised a total of $55 million to close its Series C equity financing
Bigfoot Biomedical® Announces Initial $45 Million of a Series C Financing Led by Abbott
Bigfoot Biomedical, Inc. announced today that the company has raised $45 million in the initial tranche of a Series C equity financing.
Bigfoot Biomedical Announces Partnership With Allegheny Health Network to Advance Innovative Solution for People With Diabetes
Bigfoot Biomedical, Inc., and Allegheny Health Network (AHN) – a Highmark Health company – announced today a collaboration to further advance Bigfoot Biomedical’s first-in-kind data-driven solutions for optimizing the dosing and delivery of insulin for people with diabetes.
Bigfoot Biomedical and Owen Mumford Announce Commercial Supply Agreement
Global Pen Needle Manufacturer to Supply Product for Digital Insulin Delivery Company’s Connected Injection Systems
Bigfoot Biomedical Announces Next Step for Connected Insulin Injection System
Bigfoot Biomedical, Inc. announced a non-exclusive cooperation agreement with Eli Lilly and Company (NYSE: LLY) to support integration of Lilly’s insulin products into Bigfoot’s systems currently in development.
Bigfoot Biomedical® Names Jyoti Palaniappan as Chief Commercial Officer and Ian Hanson as Chief Technology Officer
Digital Drug Delivery Company Developing Insulin Delivery Solutions Adds Commercialization Muscle to C-Suite
The round was co-led by funds managed by new investor Janus Henderson Investors.
Bigfoot Biomedical Presents Data From Clinical Research Center Trial and Simulation Modeling at Diabetes Technology Meeting
The trial provided validation for Bigfoot’s groundbreaking in-silico metabolic simulation engine.
Bigfoot Biomedical and Ypsomed Announce Agreement
Bigfoot Biomedical and Ypsomed announced that the companies have entered into an agreement under which Ypsomed will supply Bigfoot with a customized proprietary version of its Orbit infusion sets as part of Bigfoot’s investigational automated insulin pump-based solution for use in a pivotal trial.
Abbott And Bigfoot Biomedical Announce Collaboration To Develop Breakthrough Diabetes Technologies
Bay Area's Bigfoot Biomedical Pulls in $35.5 Million for Smartloop Artificial Pancreas Program
Underdog Bigfoot Biomedical Faces Medtronic and Other Players in the Artificial Pancreas Race